Mark Poznansky, MD, PhD, is an associate professor of medicine at Harvard Medical School, an attending physician in infectious diseases medicine at the Massachusetts General Hospital (MGH), and Director of the Vaccine and Immunotherapy Center at MGH. He holds a doctoral degree Cambridge University and a medical degree from University of Edinburgh. His clinical subspecialization includes the treatment of infection in immune-compromised patients.
The Poznansky laboratory works at the interface between scientific discovery and medical product development, discovering novel immune processes, defining their molecular mechanisms and exploring their relevance to the development of vaccines and immunotherapies for cancer, infectious diseases and type I diabetes. Their work is funded by the National Institutes of Health, Juvenile Diabetes Research Foundation, The Marsha Rivkin Center and other private foundations.
Dr. Poznansky brings his passion and wealth of personal experience of medical discovery, translational medicine and the development of novel products for patients to his work. He has generated a portfolio of patents at the MGH, most of which are licensed to industry or developed in partnership with private and federal organizations, including DARPA. He is also the scientific founder of Celtaxsys, VICapsys, and ACTx and is a scientific consultant to Novelos and the St. Joseph’s Translational Research Institute in Atlanta. Dr. Poznansky also served on the Innovation Liason Program at MGH, working at the interface between inventive scientists at MGH and the Mass General Brigham Ventures and Licensing Office. Dr. Poznansky is a mentor for junior scientists at MGH in the Boston Scientific Careers Program and at Cambridge University and Imperial College in England.Back to Commercialization Council